title: Low-dose palliative splenic irradiation in haematolymphoid malignancy.
abstract: Patients are treated with palliative splenic irradiation (SI) to relieve pain, volume effects and the clinical consequences of hypersplenism. The case records of 19 patients treated with palliative SI at our centre, from April 2003 to November 2004, were reviewed. Twenty-two courses of SI were identified. The radiation doses delivered ranged from 150 to 800 cGy (median 450 cGy). The fraction sizes ranged from 25 to 100 cGy. Parallel-opposed anteroposterior-posteroanterior portals were the most common field arrangement. The target volume was reduced in 18 out of 22 courses. The percentage of field reduction ranged from 0 to 59.57% (mean 24.82%). Twelve of 14 courses were successful in achieving symptom palliation. Of the six patients who received SI for a combination of splenic symptoms and abnormal blood tests, five had symptomatic palliation but only one patient responded haematologically. Of two patients who were started on palliative SI for abnormal haematology alone, only one responded. In summary, 17 of 20 (85%) courses of SI initiated for symptom control resulted in effective palliation. Only two of eight (25%) courses of SI started for abnormal blood counts produced a desired response. To conclude, SI offers an effective and well-tolerated palliative treatment option.
authors.affiliation: Department of Clinical Oncology, Beatson West of Scotland Cancer Centre, Glasgow, UK. dr_shrimali@hotmail.com
authors.forename: R K
authors.initials: RK
authors.lastname: Shrimali
authors.forename: P D
authors.initials: PD
authors.lastname: Correa
authors.forename: N
authors.initials: N
authors.lastname: O'Rourke
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006801:Humans; D006971:Hypersplenism / Q000209:etiology / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000209:etiology / Q000517:prevention & control*; D010166:Palliative Care / Q000379:methods*; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D013160:Splenic Neoplasms / Q000150:complications / Q000532:radiotherapy*; D016896:Treatment Outcome